(London, UK) November 12, 2026. Naitive Technologies, a medical technology company developing AI-driven software to reimagine orthopedic care, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for OsteoSight Spine. OsteoSight Spine enables opportunistic assessment of bone mineral density (BMD) using routine lumbar spine, thoracic spine, and chest X-rays acquired to investigate other clinical concerns. An estimated 124 million lumbar spine, thoracic spine, and chest X-rays are performed in the US each year[1]. This clearance follows FDA clearance of OsteoSight for hip and pelvis X-rays in September 2025. Together, these clearances turn routine images into an opportunity to identify patients at risk of low BMD.
Naitive® Receives FDA 510(k) Clearance for OsteoSight™ Spine, Extending AI-Enabled Opportunistic Bone Health Assessment to Spine and Chest X-rays
Osteoporosis, characterized by the progressive loss of BMD, impacts millions of Americans and costs healthcare systems billions each year. Yet, 70% of patients with low BMD are undiagnosed[2], often until a fracture occurs, with vertebral fractures being the most common osteoporotic fracture[3]. Bone health is also a key determinant of surgical outcomes. In spine surgery, low BMD predicts pedicle screw loosening[4] and is associated with proximal junctional kyphosis and failure[5].
Designed with spine surgeons, neurosurgeons, and radiologists, OsteoSight Spine addresses an urgent unmet clinical need, with a solution that fits seamlessly into the existing clinical workflow. OsteoSight Spine analyzes routine lumbar spine, thoracic spine, and chest X-rays in patients 50 years and older and opportunistically identifies cases at risk for low BMD. It provides a notification in the form of a report to aid the interpreting physician and prompt a clinical assessment of bone health.
“Bone quality underpins every spine procedure, and this clearance gives spine surgeons a new way to see it. OsteoSight Spine draws on the X-rays we order every day to flag patients whose low bone density is hiding in plain sight,” said Dr. Todd Albert, Surgeon-in-Chief Emeritus, Hospital for Special Surgery. “Knowing this early lets surgeons address bone health before surgery. When spine and bone health teams work together, patients arrive better prepared and on a stronger path to recovery.”
"OsteoSight Spine marks the next step in our bone health platform," said Dr. Will Briggs, CEO of Naitive. "Spine and chest X-rays are among the most common images in medicine, and each one is a chance to catch low bone density before a fracture. With this latest clearance, we can bring proactive bone health to far more patients and give practices a clear path to act on it."
Building on the foundation laid by OsteoSight Hip, OsteoSight Spine advances a comprehensive bone health platform, designed to enable orthopedic practices to take a proactive role in bone health management, supporting earlier intervention, improved outcomes, and new growth opportunities for practices.
References
About Naitive Technologies
Naitive is a medical technology company developing AI-driven software to reimagine orthopedic care. We are dedicated to solving urgent challenges in musculoskeletal health by building intelligent, pathway-driven technologies that help orthopedic providers surface at-risk patients, convert them to treatment, and coordinate their care – ensuring that every high-risk patient is identified early, treated appropriately, and supported throughout their journey.
OsteoSight™, our flagship technology, enables opportunistic assessment of low bone mineral density (BMD) from routine hip, pelvis, spine, and chest X-rays, seamlessly embedding bone health into the orthopedic care pathway. By driving earlier intervention, enabling more informed surgical planning, and addressing the urgent need to reduce osteoporotic fractures, OsteoSight exemplifies our mission to redefine how care is delivered – making better outcomes and stronger health systems a reality.
Built on academic leadership from Oxford and Cambridge and in collaboration with world-leading healthcare systems, Naitive is powering the future of orthopedic care.
Discover more at naitive.com.
Media Contact
Dr. Cat Kelly, Chief Operating Officer
Author
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Naitive Technologies secured FDA 510(k) clearance for OsteoSight Spine, expanding its AI-driven bone health assessment to spine and chest X-rays. This strategic move leverages an estimated 124 million annual US X-rays, offering significant market penetration by identifying undiagnosed low BMD patients. It creates new growth opportunities for orthopedic practices by integrating proactive bone health management seamlessly into existing workflows, potentially improving surgical outcomes and patient care pathways.
- This clearance follows OsteoSight for hip/pelvis X-rays, establishing a comprehensive bone health platform.
- The system aims to improve surgical outcomes and generate new revenue streams for practices through early intervention.
PhD Lens: Clinical and outcomes impact
Naitive's OsteoSight Spine, an AI-driven software, received FDA 510(k) clearance for opportunistic bone mineral density (BMD) assessment. It analyzes routine lumbar, thoracic, and chest X-rays in patients 50+ to identify low BMD risk. This system provides a report to guide interpreting physicians, addressing the high rate of undiagnosed osteoporosis and its impact on vertebral fractures and spine surgery outcomes like pedicle screw loosening.
- The software identifies low BMD risk from existing X-rays, prompting clinical assessment without requiring new imaging.
- Low BMD is a critical factor in spine surgery, predicting complications such as pedicle screw loosening and proximal junctional kyphosis.
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.